All data are based on the daily closing price as of November 18, 2026
g

GNI Group

2160.TSE
13.99 USD
-0.43
-2.98%

Overview

Last close
13.99 usd
Market cap
920.61M usd
52 week high
30.23 usd
52 week low
12.67 usd
Target price
27.62 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
4.0535
Price/Book Value
2.3227
Enterprise Value
1.30B usd
EV/Revenue
5.5502
EV/EBITDA
297.0235

Key financials

Revenue TTM
233.64M usd
Gross Profit TTM
147.80M usd
EBITDA TTM
2.10M usd
Earnings per Share
-0.62 usd
Dividend
N/A usd
Total assets
1.30B usd
Net debt
399.29M usd

About

GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for the treatment of pneumoconiosis, dermatomyositis interstitial lung disease, and systemic sclerosis-associated interstitial lung disease; and F351 which is in Phase III clinical trial for the treatment of chronic hepatitis B liver fibrosis. In addition, the company is involved in the development of ETUARY which is in Phase II clinical trial for the treatment of radiation-induced lung injury with or without immune-related pneumonitis; F573 which is in Phase II clinical trial for the treatment of acute liver failure and acute-on-chronic liver failure; F351 which is in Phase I clinical trial for the treatment of MASH-advanced liver fibrosis; and F230 which is in Phase I clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops CG001419 which is in Phase Ia clinical trial for the treatment of acute and chronic pain; CG001419 which is in Phase Ia clinical trial for the treatment of solid tumors; and CG009301 which is in Phase Ia clinical trial for the treatment of leukemia and MYC+ cancers. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
  • Symbol
    2160.TSE
  • Exchange
    TSE
  • Isin
    JP3386370005
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Dr. Ying Luo Ph.D.
  • Headquarter
    Chuo
  • Web site
    https://www.gnipharma.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top